Connor Clark & Lunn Investment Management LTD Has Boosted Aon Plc (AON) Stake; Ironwood Pharmaceuticals, Inc. (IRWD) Had 3 Bulls

August 12, 2018 - By Megan Stone

Aon plc (NYSE:AON) Logo

Among 7 analysts covering Ironwood Pharma (NASDAQ:IRWD), 3 have Buy rating, 2 Sell and 2 Hold. Therefore 43% are positive. Ironwood Pharma had 10 analyst reports since March 12, 2018 according to SRatingsIntel. As per Wednesday, May 2, the company rating was upgraded by Mizuho. Mizuho maintained Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) rating on Thursday, May 31. Mizuho has “Buy” rating and $2400 target. Mizuho maintained it with “Hold” rating and $16.0 target in Monday, March 12 report. As per Thursday, May 31, the company rating was maintained by Wells Fargo. The stock has “Underweight” rating by Morgan Stanley on Wednesday, May 9. The rating was maintained by Wells Fargo on Thursday, August 9 with “Outperform”. The rating was initiated by Berenberg with “Buy” on Thursday, April 19. The firm has “Market Perform” rating by Cowen & Co given on Wednesday, July 18. See Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) latest ratings:

09/08/2018 Broker: Wells Fargo Old Rating: Outperform New Rating: Outperform Old Target: $22 New Target: $23 Maintain
23/07/2018 Broker: H.C. Wainwright Rating: Sell New Target: $12.5 Initiates Coverage On
18/07/2018 Broker: Cowen & Co Old Rating: Outperform New Rating: Market Perform Downgrade
31/05/2018 Broker: Mizuho Rating: Buy New Target: $24.0000 Maintain
31/05/2018 Broker: Wells Fargo Old Rating: Outperform New Rating: Outperform Old Target: $18 New Target: $20 Maintain
09/05/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Underweight Downgrade
02/05/2018 Broker: Barclays Capital Rating: Hold New Target: $20.0000
02/05/2018 Broker: Mizuho Old Rating: Neutral New Rating: Buy Upgrade
19/04/2018 Broker: Berenberg Rating: Buy New Target: $25.0000 Initiate
12/03/2018 Broker: Mizuho Rating: Hold New Target: $16.0 Maintain

Connor Clark & Lunn Investment Management Ltd increased Aon Plc (AON) stake by 15.55% reported in 2018Q1 SEC filing. Connor Clark & Lunn Investment Management Ltd acquired 18,350 shares as Aon Plc (AON)’s stock declined 0.75%. The Connor Clark & Lunn Investment Management Ltd holds 136,354 shares with $19.14 million value, up from 118,004 last quarter. Aon Plc now has $34.40B valuation. The stock decreased 0.85% or $1.22 during the last trading session, reaching $141.76. About 659,597 shares traded. Aon plc (NYSE:AON) has risen 9.13% since August 12, 2017 and is uptrending. It has underperformed by 3.44% the S&P500. Some Historical AON News: 23/03/2018 – MOVES-Aon UK appoints Nathan Shanaghy as COO; 06/03/2018 – MOVES-State Street, Aon, HSBC, Moelis; 16/03/2018 – Aon PLC: Robert S. Morrison to Retire From Board June 22; 16/03/2018 – 12 Experts From Aon’s Assessment Solutions Will Present at SIOP 2018; 25/04/2018 – AON AON IBERIA BUYS INSPIRING BENEFITS, A LEADING PROVIDER OF L; 23/03/2018 – AON UK LTD NAMES NEW COO; 25/04/2018 – Aon chief warns sector must innovate or lose relevance; 03/05/2018 – Mackenzie Canadian Growth Adds Aon, Exits Marsh & McLennan; 13/03/2018 – Aon survey: falling employee engagement in Canada is a “wake-up call” for employers; 10/04/2018 – AON PLC – CO, HP ANNOUNCE STRATEGIC COLLABORATION FOR COMPREHENSIVE IT SECURITY AND CYBER RISK MANAGEMENT SERVICES

Connor Clark & Lunn Investment Management Ltd decreased Bhp Billiton Ltd. Spons Adr (NYSE:BHP) stake by 205,800 shares to 151,976 valued at $6.75M in 2018Q1. It also reduced Mag Silver (NYSEMKT:MVG) stake by 52,737 shares and now owns 95,245 shares. Costco Wholesale Inc. (NASDAQ:COST) was reduced too.

Among 4 analysts covering Aon (NYSE:AON), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Aon had 7 analyst reports since February 20, 2018 according to SRatingsIntel. Barclays Capital maintained Aon plc (NYSE:AON) rating on Tuesday, February 20. Barclays Capital has “Equal-Weight” rating and $138 target. Citigroup maintained the stock with “Buy” rating in Tuesday, March 27 report. On Tuesday, May 8 the stock rating was maintained by Citigroup with “Buy”. The firm has “Buy” rating by Citigroup given on Tuesday, April 10. The stock of Aon plc (NYSE:AON) has “Buy” rating given on Wednesday, February 28 by Citigroup. The company was upgraded on Thursday, March 15 by Goldman Sachs.

More recent Aon plc (NYSE:AON) news were published by: Benzinga.com which released: “Earnings Outlook For Aon” on July 26, 2018. Also Seekingalpha.com published the news titled: “Aon Corporation (AON) CEO Greg Case on Q2 2018 Results – Earnings Call Transcript” on July 27, 2018. Businesswire.com‘s news article titled: “Insurance Labor Outlook Study Results to be Revealed During Webinar” with publication date: August 07, 2018 was also an interesting one.

Since February 21, 2018, it had 0 buys, and 10 selling transactions for $1.53 million activity. MCCOURT Thomas A also sold $600,000 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Friday, July 6. The insider McHugh Julie sold 1,500 shares worth $26,430. Consylman Gina also sold $52,688 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares. Shares for $35,240 were sold by OLANOFF LAWRENCE S. $113,483 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) was sold by Gilbert Halley E. The insider Currie Mark G sold $23,954.

The stock decreased 2.03% or $0.39 during the last trading session, reaching $18.82. About 652,092 shares traded. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has declined 9.49% since August 12, 2017 and is downtrending. It has underperformed by 22.06% the S&P500. Some Historical IRWD News: 09/04/2018 – Ironwood Pharma: Sarissa Capital Intends to Nominate Alex Denner to Stand for Election to Board; 03/05/2018 – ALLERGAN – SETTLEMENT WITH AUROBINDO IS SECOND PATENT INFRINGEMENT SETTLEMENT COMPANIES HAVE REACHED WITH RESPECT TO LINZESS; 09/04/2018 – lronwood Pharmaceuticals Announces Director Nomination from Sarissa Capital; 31/05/2018 – Sarissa Capital Issues Statement On Ironwood Pharmaceuticals; 31/05/2018 – Sarissa Cap Issues Statement on Ironwood Pharmaceuticals; 09/04/2018 – Ironwood Pharmaceuticals Announces Director Nomination From Sarissa Cap; 09/05/2018 – lronwood Pharmaceuticals Files Investor Presentation Highlighting Actions Taken Designed to Unlock Shareholder Value; 09/04/2018 – IRONWOOD PHARMACEUTICALS REPORTS DIRECTOR NOMINATION FROM SARIS; 31/05/2018 – Sarissa Capital Issues Statement On lronwood Pharmaceuticals; 03/05/2018 – Ironwood and Allergan Announce Settlement with Aurobindo Pharma Resolving LINZESS® (linaclotide) Patent Litigation

More notable recent Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) news were published by: Nasdaq.com which released: “Factors of Influence in 2018, Key Indicators and Opportunity within Omnicom Group, Ironwood Pharmaceuticals …” on August 09, 2018, also Seekingalpha.com with their article: “Ironwood Pharma Q2 revenues up 25%” published on August 06, 2018, Seekingalpha.com published: “Ironwood Pharmaceuticals, Inc. (IRWD) CEO Peter Hecht on Q2 2018 Results – Earnings Call Transcript” on August 06, 2018. More interesting news about Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) were released by: Nasdaq.com and their article: “Ironwood Begins New Phase III Study to Expand Linzess Label” published on July 17, 2018 as well as Seekingalpha.com‘s news article titled: “Premarket analyst action – healthcare” with publication date: July 23, 2018.

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company has market cap of $2.88 billion. The firm markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It currently has negative earnings. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts